143 related articles for article (PubMed ID: 29309757)
1. Doxorubicin resistance in breast cancer: A novel role for the human protein AHNAK.
Davis T; van Niekerk G; Peres J; Prince S; Loos B; Engelbrecht AM
Biochem Pharmacol; 2018 Feb; 148():174-183. PubMed ID: 29309757
[TBL] [Abstract][Full Text] [Related]
2. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
3. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS
Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
5. Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Eur J Pharm Sci; 2017 Jun; 104():424-433. PubMed ID: 28455002
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of breast cancer cells to doxorubicin via stable cell line generation and overexpression of DFF40.
Bagheri F; Safarian S; Eslaminejad MB; Sheibani N
Biochem Cell Biol; 2015 Dec; 93(6):604-10. PubMed ID: 26529233
[TBL] [Abstract][Full Text] [Related]
7. iTRAQ-based proteomic profiling of breast cancer cell response to doxorubicin and TRAIL.
Leong S; Nunez AC; Lin MZ; Crossett B; Christopherson RI; Baxter RC
J Proteome Res; 2012 Jul; 11(7):3561-72. PubMed ID: 22587632
[TBL] [Abstract][Full Text] [Related]
8. Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway.
Liu WH; Chang LS
Int J Biochem Cell Biol; 2011 Dec; 43(12):1708-19. PubMed ID: 21854868
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of SALL4 inhibits the proliferation and reverses the resistance of MCF-7/ADR cells to doxorubicin hydrochloride.
Chen YY; Li ZZ; Ye YY; Xu F; Niu RJ; Zhang HC; Zhang YJ; Liu YB; Han BS
BMC Mol Biol; 2016 Mar; 17():6. PubMed ID: 26935744
[TBL] [Abstract][Full Text] [Related]
10. Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1.
Qin T; Huang G; Chi L; Sui S; Song C; Li N; Sun S; Li N; Zhang M; Zhao Z; Li L; Li M
Biomed Pharmacother; 2017 Nov; 95():649-655. PubMed ID: 28881292
[TBL] [Abstract][Full Text] [Related]
11. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
12. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
Wang Z; Kong J; Wu Y; Zhang J; Wang T; Li N; Fan J; Wang H; Zhang J; Ling R
Breast Cancer Res Treat; 2018 Apr; 168(2):531-542. PubMed ID: 29185119
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin-protein ligase E3C maintains non-small-cell lung cancer stemness by targeting AHNAK-p53 complex.
Gu J; Mao W; Ren W; Xu F; Zhu Q; Lu C; Lin Z; Zhang Z; Chu Y; Liu R; Ge D
Cancer Lett; 2019 Feb; 443():125-134. PubMed ID: 30503554
[TBL] [Abstract][Full Text] [Related]
14. Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin.
Chekhun VF; Lukyanova NY; Burlaka CA; Bezdenezhnykh NA; Shpyleva SI; Tryndyak VP; Beland FA; Pogribny IP
Int J Oncol; 2013 Nov; 43(5):1481-6. PubMed ID: 23969999
[TBL] [Abstract][Full Text] [Related]
15. Silencing overexpression of FXYD3 protein in breast cancer cells amplifies effects of doxorubicin and γ-radiation on Na(+)/K(+)-ATPase and cell survival.
Liu CC; Teh R; Mozar CA; Baxter RC; Rasmussen HH
Breast Cancer Res Treat; 2016 Jan; 155(2):203-13. PubMed ID: 26740212
[TBL] [Abstract][Full Text] [Related]
16. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
17. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
18. Rack1 Mediates the Interaction of P-Glycoprotein with Anxa2 and Regulates Migration and Invasion of Multidrug-Resistant Breast Cancer Cells.
Yang Y; Wu N; Wang Z; Zhang F; Tian R; Ji W; Ren X; Niu R
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754360
[TBL] [Abstract][Full Text] [Related]
19. Ultrasound reverses chemoresistance in breast cancer stem cell like cells by altering ABCG2 expression.
Guo L; Zheng P; Fan H; Wang H; Xu W; Zhou W
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28935760
[TBL] [Abstract][Full Text] [Related]
20. Potent killing of paclitaxel- and doxorubicin-resistant breast cancer cells by calphostin C accompanied by cytoplasmic vacuolization.
Guo B; Hembruff SL; Villeneuve DJ; Kirwan AF; Parissenti AM
Breast Cancer Res Treat; 2003 Nov; 82(2):125-41. PubMed ID: 14692656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
